Samrat Pharmachem ‘s Q1 Report: Revenue Rises by 40.61% YoY

The comprehensive analytics outlining the performance and outlook of Samrat Pharmachem Ltd.‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Samrat Pharmachem Ltd.’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 40.61 %. However, it did see a marginal slip of -2.25 % from the previous quarter. Expenses decreased slightly by -3.79 % quarter-on-quarter, aligning with the annual rise of 37.97 %. Operating profit, while up 235.06 % compared to last year, faced a quarter-on-quarter increase of 89.71 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 1.85 %, but an expansion of 1.55 % sequentially. Other income rose by 95.33 % compared to the last quarter, despite an annual growth of 60.99 %. Interest expenses surged remarkably by 72.73 % from the previous quarter, yet the year-over-year decrease remains at a moderate -13.64 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax grew annually by 276 % but saw an increase from the preceding quarter by 102.88 %.
Tax expenses as a percentage of profits increased slightly by 7.86 % compared to last year, with a more notable quarter-on-quarter increase of 26.29 %. Net profit rose by 239.34 % year-on-year but experienced a 47.86 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 237.37 % but a quarterly rise of 47.79 %. In summary, Samrat Pharmachem Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Samrat Pharmachem Ltd.’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 40.61 % year-on-year growth, although there was a slight dip of -2.25 % from the previous quarter. Expenses rose by 37.97 % compared to the previous year, with a decrease of -3.79 % quarter-on-quarter. Operating Profit surged by 235.06 % annually, and saw a 89.71 % increase from the last quarter.
Net Profit showed yearly increase of 239.34 %, and experienced a 47.86 % increase from the previous quarter. Earnings Per Share (EPS) rose by 237.37 % annually, however rose by 47.79 % compared to the last quarter. In essence, while Samrat Pharmachem Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.